



225545

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID:		Date: Patient Date Of Birth:		3/31/2025				
	ient Group No:	NPI#:	Patient Phone:	Physician Name: Specialty: Physician Office Telephone				
Phy	sician Office Address:							
Dru	g Name (specify drug)			-				
Qua	antity:	Frequency: _	Strength	th:				
Con								
Ple a	ase check the appropriat What is the diagnosis?	e answer for each applica	able question.					
	Adenosine deaminase go to 2)	e severe combined immune	deficiency (ADA-SCID) (If checked,					
	Other, please specify.	(If checked, no further que	stions)					
2.	Will the requested media or a physician who spec storage disorders?	cation be prescribed by an orializes in the treatment of m	or in consultation with an immunologist netabolic disease and/or lysosomal	Y		N		
3.	(dATP) or trough deoxya REQUIRED: If Yes, atta the diagnosis.	adenosine nucleotide (dAXF	d cell deoxyadenosine triphosphate P) concentrations? ACTION t results or medical records confirming	Y		N		
4.	activity in red blood cells results or medical record	bsent or very low (<1% of n ?? ACTION REQUIRED: If \ ds confirming the diagnosis. Submit supporting docume	ormal) adenosine deaminase (ADA) /es, attach genetic or molecular test	Y		N		
5.	REQUIRED: If Yes, atta the diagnosis.	tically confirmed by biallelic ch genetic or molecular test Submit supporting docume	variant in the ADA gene? ACTION tresults or medical records confirming entation	Y		N		
6.	total lymphocyte counts values for plasma adeno triphosphate (dATP), tro lymphocyte counts.	been obtained? ACTION R osine deaminase (ADA) acti	blood cell dATP, dAXP levels, and/or EQUIRED: If Yes, attach baseline vity, red blood cell deoxyadenosine otide (dAXP) levels, and/or total entation	Y		N		
7.	Will the requested medic cell transplantation (HSC		finitive therapy with hematopoietic stem	ηΥ		N		
8.	Has the patient failed HS	SCT?		Υ		N		
9.	Is the patient a suitable available)?	candidate for HSCT (e.g., n	natched sibling or family donor	Υ		N		
10.	ACTION REQUIRED: If	No, attach hematologic ass	atelets less than 50,000/microL)? essment (e.g., complete blood count) a (platelets less than 50,000/microL).	Y		N		

ļ				
	ACTION REQUIRED: Submit supporting documentation			
11.	Does the patient have an autoimmune disease requiring immunosuppressive therapy?	Υ	N	
12.	Will the patient be monitored for evidence of treatment efficacy per protocol outlined in the prescribing information during treatment with the requested drug?	Y	N	
13.	Is this request for continuation of treatment with the requested drug?	Υ	N	
14.	Does the member have unacceptable toxicity (e.g., severe injection site reactions/bleeding, severe thrombocytopenia)?	Υ	N	
15.	Is the patient experiencing benefit from therapy (e.g., maintenance of target trough plasma ADA activity greater than 30 mmol/L, trough erythrocyte dAXP levels below 0.02 mmol/L, improved or stabilized total lymphocyte counts and/or immune function)? ACTION REQUIRED: If Yes, please attach chart notes, lab values, or medical record documentation supporting positive clinical response. ACTION REQUIRED: Submit supporting documentation	Y	N	
and to	st that the medication requested is medically necessary for this patient. I further attest that the informatic rue, and that the documentation supporting this information is available for review if requested by the clais sponsor, or, if applicable a state or federal regulatory agency.			

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.